{"entity":{"id":"paper-checkmate-214-nejm-2018","kind":"paper","name":"CheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma","aka":[],"tldr":"Dual immunotherapy with nivolumab and ipilimumab lengthened survival compared with sunitinib in intermediate- and poor-risk advanced kidney cancer, with about one in ten patients achieving a complete response that has proved durable over years.","summary":"Phase 3 trial of 1,096 patients with untreated advanced clear cell renal cell carcinoma randomised to nivolumab plus ipilimumab (four doses) followed by nivolumab, or sunitinib, with co-primary endpoints in intermediate- and poor-risk patients.\n\nIn intermediate and poor risk, 18-month overall survival was 75 versus 60 percent (hazard ratio 0.63), response 42 versus 27 percent and complete response 9 versus 1 percent; favourable-risk patients had higher response to sunitinib at first analysis. Long-term follow-up shows sustained survival benefit.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2018","url":"https://doi.org/10.1056/NEJMoa1712126"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29562145/"}],"tags":[],"related":[],"cancers":["clear-cell-rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["ipilimumab","nivolumab","sunitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-214"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2018,"doi":"10.1056/NEJMoa1712126","pmid":"29562145","authors":"Motzer RJ, Tannir NM, McDermott DF, et al.","paperType":"rct","findings":["Intermediate and poor risk: 18-month overall survival 75 percent vs 60 percent; hazard ratio 0.63.","Complete response 9 percent vs 1 percent."],"whatItMeans":"Nivolumab-ipilimumab is a first-line standard for intermediate- and poor-risk clear cell kidney cancer, notable for durable complete responses and treatment-free intervals.","caveats":["Favourable-risk patients showed no clear benefit.","Immune-related adverse events requiring high-dose steroids in about a third."],"changedPractice":true,"participants":1096},"route":"/key-papers/paper-checkmate-214-nejm-2018/","neighbours":{"cancer":[{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"trial":[{"id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}